|
WO2019165349A1
|
|
METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPß INHIBITORS
|
|
US2018092883A1
|
|
Phosphatase inhibitors for treating ocular diseases
|
|
CN109715189A
|
|
Target the Humanized monoclonal antibodies of VE-PTP (HPTP- β)
|
|
EP3352856A1
|
|
Methods of treating intraocular pressure with activators of tie-2
|
|
WO2016049183A1
|
|
Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
|
|
WO2016022813A1
|
|
Combination of immunotherapies with activators of tie-2
|
|
US2015259335A1
|
|
HPTP-β inhibitors
|
|
WO2015126860A1
|
|
Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones
|
|
EP3607821A1
|
|
Compositions, formulations and methods for treating ocular diseases
|
|
US2015050277A1
|
|
Compositions and methods for treating ocular diseases
|
|
US2014249100A1
|
|
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
|
US2014179693A1
|
|
Methods for treating vascular leak syndrome
|
|
CN104066448A
|
|
Treatment of ocular disease
|
|
US2013023542A1
|
|
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US2013023543A1
|
|
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
AU2010314982A1
|
|
Compositions and methods for treating colitis
|
|
MY158804A
|
|
Methods for treating vascular leak syndrome
|
|
CN103976998A
|
|
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
|
CN108635350A
|
|
The method for treating vascular leak syndrome
|
|
EP2592073A2
|
|
Human protein tyrosine phosphatase inhibitors and their use
|
